Early-stage preclinical and Phase 1 development of multiple hantavirus vaccine candidates, including mRNA platforms from Moderna-Korea University collaborations and UTMB single-dose formulations, underpins the 96.5% market-implied probability against approval or availability in 2026. Promising animal protection data emerged in mid-2026, yet no candidates have advanced beyond initial human safety testing, with no Phase 3 trials underway amid strain diversity and standard regulatory timelines. Existing inactivated vaccines remain limited to parts of Asia without broader approval. An unanticipated major outbreak triggering emergency authorization could theoretically accelerate progress, though current surveillance and trial schedules indicate this remains improbable before year-end.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
4% шанс
$136,356 Обс.
$136,356 Обс.
Dec 31, 2026
4% шанс
$136,356 Обс.
$136,356 Обс.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Early-stage preclinical and Phase 1 development of multiple hantavirus vaccine candidates, including mRNA platforms from Moderna-Korea University collaborations and UTMB single-dose formulations, underpins the 96.5% market-implied probability against approval or availability in 2026. Promising animal protection data emerged in mid-2026, yet no candidates have advanced beyond initial human safety testing, with no Phase 3 trials underway amid strain diversity and standard regulatory timelines. Existing inactivated vaccines remain limited to parts of Asia without broader approval. An unanticipated major outbreak triggering emergency authorization could theoretically accelerate progress, though current surveillance and trial schedules indicate this remains improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Ринок відкрито: May 4, 2026, 10:39 AM ET
Обсяг
$136,356Дата завершення
Jan 1, 2027Ринок відкрито
May 4, 2026, 10:39 AM ETВирішувач
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Early-stage preclinical and Phase 1 development of multiple hantavirus vaccine candidates, including mRNA platforms from Moderna-Korea University collaborations and UTMB single-dose formulations, underpins the 96.5% market-implied probability against approval or availability in 2026. Promising animal protection data emerged in mid-2026, yet no candidates have advanced beyond initial human safety testing, with no Phase 3 trials underway amid strain diversity and standard regulatory timelines. Existing inactivated vaccines remain limited to parts of Asia without broader approval. An unanticipated major outbreak triggering emergency authorization could theoretically accelerate progress, though current surveillance and trial schedules indicate this remains improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Обсяг
$136,356Дата завершення
Jan 1, 2027Ринок відкрито
May 4, 2026, 10:39 AM ETВирішувач
0x65070BE91...Early-stage preclinical and Phase 1 development of multiple hantavirus vaccine candidates, including mRNA platforms from Moderna-Korea University collaborations and UTMB single-dose formulations, underpins the 96.5% market-implied probability against approval or availability in 2026. Promising animal protection data emerged in mid-2026, yet no candidates have advanced beyond initial human safety testing, with no Phase 3 trials underway amid strain diversity and standard regulatory timelines. Existing inactivated vaccines remain limited to parts of Asia without broader approval. An unanticipated major outbreak triggering emergency authorization could theoretically accelerate progress, though current surveillance and trial schedules indicate this remains improbable before year-end.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання